Publications by Angelina Hatlø Maniaol

24 publications found

Publications 2024

1. Howard JF, Bresch S, Farmakidis C, Freimer M, Genge A, Hewamadduma C, Hinton J, Hussain Y, Juntas-Morales R, Kaminski HJ, Maniaol A, Mantegazza R, Masuda M, Nowak RJ, Sivakumar K, Śmiłowski M, Utsugisawa K, Vu T, Weiss MD, Zajda M, Bloemers J, Boroojerdi B, Brock M, de la Borderie G, Duda PW et al. (2024)
   Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study
   Ther Adv Neurol Disord, 17, 17562864241243186
   DOI 10.1177/17562864241243186, PubMed 38638673
2. Novy C, Busk ØL, Tysnes OB, Landa SS, Aanjesen TN, Alstadhaug KB, Bjerknes TL, Bjørnå IK, Bråthen G, Dahl E, Demic N, Fahlström M, Flemmen HØ, Hallerstig E, HogenEsch I, Kampman MT, Kleveland G, Kvernmo HB, Ljøstad U, Maniaol A, Morsund AH, Nakken O, Olsen CG, Schlüter K, Utvik MS et al. (2024)
   Repeat expansions in AR, ATXN1, ATXN2 and HTT in Norwegian patients diagnosed with amyotrophic lateral sclerosis
   Brain Commun, 6 (2), fcae087
   DOI 10.1093/braincomms/fcae087, PubMed 38585669
3. Olsen CG, Malmberg VN, Fahlström M, Alstadhaug KB, Bjørnå IK, Braathen GJ, Bråthen G, Demic N, Hallerstig E, Hogenesch I, Horn MA, Kampman MT, Kleveland G, Ljøstad U, Maniaol A, Morsund ÅH, Nakken O, Schlüter K, Schuler S, Seim E, Flemmen HØ, Tysnes OB, Holmøy T, Høyer H (2024)
   Amyotrophic lateral sclerosis caused by the C9orf72 expansion in Norway - prevalence, ancestry, clinical characteristics and sociodemographic status
   Amyotroph Lateral Scler Frontotemporal Degener, 1-9 (in press)
   DOI 10.1080/21678421.2024.2405118, PubMed 39316038
4. Weiss MD, Freimer M, Leite MI, Maniaol A, Utsugisawa K, Bloemers J, Boroojerdi B, Howard E, Savic N, Howard JF (2024)
   Improvement of fatigue in generalised myasthenia gravis with zilucoplan
   J Neurol, 271 (5), 2758-2767
   DOI 10.1007/s00415-024-12209-3, PubMed 38400914

Publications 2023

1. Howard JF, Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y, Juntas-Morales R, Kaminski HJ, Maniaol A, Mantegazza R, Masuda M, Sivakumar K, Śmiłowski M, Utsugisawa K, Vu T, Weiss MD, Zajda M, Boroojerdi B, Brock M, de la Borderie G, Duda PW, Lowcock R, Vanderkelen M, Leite MI, RAISE Study Team (2023)
   Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
   Lancet Neurol, 22 (5), 395-406
   DOI 10.1016/S1474-4422(23)00080-7, PubMed 37059508

Publications 2022

1. Olsen CG, Busk ØL, Aanjesen TN, Alstadhaug KB, Bjørnå IK, Braathen GJ, Breivik KL, Demic N, Flemmen HØ, Hallerstig E, HogenEsch I, Holla ØL, Jøntvedt AB, Kampman MT, Kleveland G, Kvernmo HB, Ljøstad U, Maniaol A, Morsund ÅH, Nakken O, Novy C, Rekand T, Schlüter K, Schüler S, Tveten K et al. (2022)
   Genetic Epidemiology of Amyotrophic Lateral Sclerosis in Norway: A 2-Year Population-Based Study
   Neuroepidemiology, 56 (4), 271-282
   DOI 10.1159/000525091, PubMed 35576897

Publications 2021

1. Creary LE, Gangavarapu S, Caillier SJ, Cavalcante P, Frangiamore R, Lie BA, Bengtsson M, Harbo HF, Brauner S, Hollenbach JA, Oksenberg JR, Bernasconi P, Maniaol AH, Hammarström L, Mantegazza R, Fernández-Viña MA (2021)
   Next-Generation Sequencing Identifies Extended HLA Class I and II Haplotypes Associated With Early-Onset and Late-Onset Myasthenia Gravis in Italian, Norwegian, and Swedish Populations
   Front Immunol, 12, 667336
   DOI 10.3389/fimmu.2021.667336, PubMed 34163474

Publications 2018

1. Vincent A, Huda S, Cao M, Cetin H, Koneczny I, Rodriguez Cruz PM, Jacobson L, Viegas S, Jacob S, Woodhall M, Nagaishi A, Maniaol A, Damato V, Leite MI, Cossins J, Webster R, Palace J, Beeson D (2018)
   Serological and experimental studies in different forms of myasthenia gravis
   Ann N Y Acad Sci, 1413 (1), 143-153
   DOI 10.1111/nyas.13592, PubMed 29377162

Publications 2017

1. Boldingh MI, Maniaol A, Brunborg C, Dekker L, Lipka A, Niks EH, Verschuuren J, Tallaksen C (2017)
   Prevalence and clinical aspects of immigrants with myasthenia gravis in northern Europe
   Muscle Nerve, 55 (6), 819-827
   DOI 10.1002/mus.25408, PubMed 27641227
2. Huda S, Waters P, Woodhall M, Leite MI, Jacobson L, De Rosa A, Maestri M, Ricciardi R, Heckmann JM, Maniaol A, Evoli A, Cossins J, Hilton-Jones D, Vincent A (2017)
   IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG
   Neurol Neuroimmunol Neuroinflamm, 4 (4), e357
   DOI 10.1212/NXI.0000000000000357, PubMed 28626780

Publications 2016

1. Boldingh MI, Maniaol AH, Brunborg C, Weedon-Fekjær H, Verschuuren JJ, Tallaksen CM (2016)
   Increased risk for clinical onset of myasthenia gravis during the postpartum period
   Neurology, 87 (20), 2139-2145
   DOI 10.1212/WNL.0000000000003339, PubMed 27770065
2. Popperud TH, Boldingh MI, Brunborg C, Faiz KW, Heldal AT, Maniaol AH, Müller KI, Rasmussen M, Øymar K, Kerty E (2016)
   Juvenile myasthenia gravis in Norway: A nationwide epidemiological study
   Eur J Paediatr Neurol, 21 (2), 312-317
   DOI 10.1016/j.ejpn.2016.09.001, PubMed 27666466
3. Stergiou C, Lazaridis K, Zouvelou V, Tzartos J, Mantegazza R, Antozzi C, Andreetta F, Evoli A, Deymeer F, Saruhan-Direskeneli G, Durmus H, Brenner T, Vaknin A, Berrih-Aknin S, Behin A, Sharshar T, De Baets M, Losen M, Martinez-Martinez P, Kleopa KA, Zamba-Papanicolaou E, Kyriakides T, Kostera-Pruszczyk A, Szczudlik P, Szyluk B et al. (2016)
   Titin antibodies in "seronegative" myasthenia gravis--A new role for an old antigen
   J Neuroimmunol, 292, 108-15
   DOI 10.1016/j.jneuroim.2016.01.018, PubMed 26943968

Publications 2015

1. Boldingh MI, Dekker L, Maniaol AH, Brunborg C, Lipka AF, Niks EH, Verschuuren JJ, Tallaksen CM (2015)
   An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts
   Health Qual Life Outcomes, 13, 115
   DOI 10.1186/s12955-015-0298-1, PubMed 26232146
2. Boldingh MI, Maniaol AH, Brunborg C, Dekker L, Heldal AT, Lipka AF, Popperud TH, Niks EH, Verschuuren JJ, Tallaksen CM (2015)
   Geographical Distribution of Myasthenia Gravis in Northern Europe--Results from a Population-Based Study from Two Countries
   Neuroepidemiology, 44 (4), 221-31
   DOI 10.1159/000431036, PubMed 26068011
3. Seldin MF, Alkhairy OK, Lee AT, Lamb JA, Sussman J, Pirskanen-Matell R, Piehl F, Verschuuren JJGM, Kostera-Pruszczyk A, Szczudlik P, McKee D, Maniaol AH, Harbo HF, Lie BA, Melms A, Garchon HJ, Willcox N, Gregersen PK, Hammarstrom L (2015)
   Genome-Wide Association Study of Late-Onset Myasthenia Gravis: Confirmation of TNFRSF11A and Identification of ZBTB10 and Three Distinct HLA Associations
   Mol Med, 21 (1), 769-781
   DOI 10.2119/molmed.2015.00232, PubMed 26562150
4. Tsonis AI, Zisimopoulou P, Lazaridis K, Tzartos J, Matsigkou E, Zouvelou V, Mantegazza R, Antozzi C, Andreetta F, Evoli A, Deymeer F, Saruhan-Direskeneli G, Durmus H, Brenner T, Vaknin A, Berrih-Aknin S, Behin A, Sharshar T, De Baets M, Losen M, Martinez-Martinez P, Kleopa KA, Zamba-Papanicolaou E, Kyriakides T, Kostera-Pruszczyk A et al. (2015)
   MuSK autoantibodies in myasthenia gravis detected by cell based assay--A multinational study
   J Neuroimmunol, 284, 10-7
   DOI 10.1016/j.jneuroim.2015.04.015, PubMed 26025053

Publications 2014

1. Avidan N, Le Panse R, Harbo HF, Bernasconi P, Poulas K, Ginzburg E, Cavalcante P, Colleoni L, Baggi F, Antozzi C, Truffault F, Horn-Saban S, Pöschel S, Zagoriti Z, Maniaol A, Lie BA, Bernard I, Saoudi A, Illes Z, Casasnovas Pons C, Melms A, Tzartos S, Willcox N, Kostera-Pruszczyk A, Tallaksen C et al. (2014)
   VAV1 and BAFF, via NFκB pathway, are genetic risk factors for myasthenia gravis
   Ann Clin Transl Neurol, 1 (5), 329-39
   DOI 10.1002/acn3.51, PubMed 25356403

Publications 2013

1. Zisimopoulou P, Evangelakou P, Tzartos J, Lazaridis K, Zouvelou V, Mantegazza R, Antozzi C, Andreetta F, Evoli A, Deymeer F, Saruhan-Direskeneli G, Durmus H, Brenner T, Vaknin A, Berrih-Aknin S, Frenkian Cuvelier M, Stojkovic T, DeBaets M, Losen M, Martinez-Martinez P, Kleopa KA, Zamba-Papanicolaou E, Kyriakides T, Kostera-Pruszczyk A, Szczudlik P et al. (2013)
   A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis
   J Autoimmun, 52, 139-45
   DOI 10.1016/j.jaut.2013.12.004, PubMed 24373505

Publications 2012

1. Gregersen PK, Kosoy R, Lee AT, Lamb J, Sussman J, McKee D, Simpfendorfer KR, Pirskanen-Matell R, Piehl F, Pan-Hammarstrom Q, Verschuuren JJ, Titulaer MJ, Niks EH, Marx A, Ströbel P, Tackenberg B, Pütz M, Maniaol A, Elsais A, Tallaksen C, Harbo HF, Lie BA, Raychaudhuri S, de Bakker PI, Melms A et al. (2012)
   Risk for myasthenia gravis maps to a (151) Pro→Ala change in TNIP1 and to human leukocyte antigen-B*08
   Ann Neurol, 72 (6), 927-35
   DOI 10.1002/ana.23691, PubMed 23055271
2. Maniaol AH, Boldingh M, Brunborg C, Harbo HF, Tallaksen CME (2012)
   Smoking and socio-economic status may affect myasthenia gravis
   Eur J Neurol, 20 (3), 453-460
   DOI 10.1111/j.1468-1331.2012.03843.x, PubMed 22934661
3. Maniaol AH, Elsais A, Lorentzen ÅR, Owe JF, Viken MK, Sæther H, Flåm ST, Bråthen G, Kampman MT, Midgard R, Christensen M, Rognerud A, Kerty E, Gilhus NE, Tallaksen CM, Lie BA, Harbo HF (2012)
   Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population
   PLoS One, 7 (5), e36603
   DOI 10.1371/journal.pone.0036603, PubMed 22590574

Publications 2011

1. Alseth EH, Maniaol AH, Elsais A, Nakkestad HL, Tallaksen C, Gilhus NE, Skeie GO (2011)
   Investigation for RAPSN and DOK-7 mutations in a cohort of seronegative myasthenia gravis patients
   Muscle Nerve, 43 (4), 574-7
   DOI 10.1002/mus.21919, PubMed 21305573

Publications 2010

1. Maniaol AH, Brunborg C, Tallaksen CM (2010)
   Development and validation of a self-administered questionnaire for myasthenia gravis patients
   Neuroepidemiology, 34 (4), 253-61
   DOI 10.1159/000297753, PubMed 20299807